Fil LTD Arcus Biosciences, Inc. Transaction History

Fil LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$26.93 - $37.68 $981,356 - $1.37 Million	-36,441 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$22.75 - $35.77 $474,701 - $746,376	-20,866 Reduced 36.41%	36,441 $1 Million
Q1 2021 May 14, 2021	BUY	$26.16 - $41.39 $1.49 Million - $2.35 Million	56,879 Added 13289.49%	57,307 $1.61 Million
Q4 2020 Feb 08, 2021	BUY	$17.0 - $32.36 $2,006 - $3,818	118 Added 38.06%	428 $11,000
Q3 2020 Nov 13, 2020	BUY	$17.14 - $25.47 $2,159 - $3,209	126 Added 68.48%	310 $5,000
Q2 2020 Aug 13, 2020	BUY	$13.97 - $36.56 $2,570 - $6,727	184 New	184 $5,000
Q4 2018 Feb 13, 2019	SELL	$9.74 - $14.5 $519,005 - $772,647	-53,286 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$15.44 - $17.71 $822,735 - $943,695	53,286 New	53,286 $823,000

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $950M
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Fil LTD, based on Form 13F filings with the SEC.

Stay updated on Fil LTD with notifications on news.